SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Celgene Corporation

254

Celgene

CELG

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Mark J. Alles

CEO Title

Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Summit, NJ

Years on Fortune 500 List

6

Employees

7,132

Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$11,22921.3%
Profits ($M)$1,999.224.8%
Assets ($M)$28,086
Total Stockholder Equity ($M)$6,599.3
Market Value — as of March 31, 2017 ($M)$96,802
Profit Ratios
Profit as % of Revenues17.8%
Profits as % of Assets7.1%
Profits as % of Stockholder Equity30.3%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.49
EPS % Change (from 2015)28.4%
EPS % Change (5 year annual rate)11.8%
EPS % Change (10 year annual rate)39.4%
Total Return
Total Return to Investors (2016)-3.3%
Total Return to Investors (5 year, annualized)27.9%
Total Return to Investors (10 year, annualized)14.9%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Celgene

Why Analysts Are Calling Celgene's $9 Billion Juno Acquisition a 'Smart' Biotech Deal

Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.

Read More →
Celgene Is Paying $9 Billion for Juno Therapeutics in Blockbuster Cancer Drug Deal

With Juno, Celgene will gain research into a novel class of therapies known as CAR-T.

Read More →
This 31-Year-Old CEO Is Snapping Up Drug Industry Veterans Left and Right

Former Celgene president Jackie Fouse is joining the unconventional Roivant crew.

Read More →